Eye drops for retinal disease (EVER 2022) - Oct 10, 2022 - Pres time: Oct 13, 2022; 08:45 AM - 09:10 AM; Location: Auditorium; "Eye drop formulations based on γ-cyclodextrin (γCD)-based nanoparticle aggregates were developed and deliver therapeutic concentrations of drugs (dorzolamide and dexamethasone) to both anterior and posterior segments of the eye in animal models and clinical studies...Pilot studies with dexamethasone/γCD eye drops showed clinical effect in a range of human conditions, including diabetic macular oedema, cystoid macular oedema and vitritis secondary to uveitis, inflammation after cataract surgery and postoperative treatment in trabeculectomy...OCS-01 was well-tolerated, and increased intraocular pressure was the most common adverse event. Cyclodextrin nanoparticle eye drops deliver drugs to the retina in therapeutically relevant concentrations and promise a non-invasive alternative in drug treatment of retinal diseases."
Cataract • Diabetic Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis
|